ProCE Banner Activity

GENUINE: Investigation of Ublituximab, a Novel CD20 Inhibitor, in Combination With Ibrutinib in Pts With Previously Treated High-Risk CLL

Slideset Download
Conference Coverage
The addition of ublituximab to ibrutinib improved ORR vs ibrutinib alone with a similar safety profile except for an increase in ublituximab-related infusion reactions.

Released: June 06, 2017

Expiration: June 05, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology